Trinity Biotech plc ATM Offering Agreement

Trinity Biotech plc has entered into an At the Market Offering Agreement with Lucid Capital Markets, LLC. Through this agreement, the company can sell up to $4,352,314 of its American Depositary Shares (ADSs), with each ADS representing 20 A Ordinary Shares. Lucid Capital Markets will act as the sales agent, selling the ADSs as requested by Trinity Biotech plc. The company will pay Lucid Capital Markets a commission of 3.0% of the gross sales price. This offering is being made under the company's previously filed Registration Statement on Form F-3. Additionally, Trinity Biotech plc has terminated its previous At the Market Offering Agreement with Craig-Hallum Capital Group LLC, as that program had been inactive since March 2025.